Pharmos Corp

Pharmos — Investor Presentation (June 2006)

31 slides from Pharmos's investor presentation, Jun 6, 2006

  1. Slide 1: Investor Presentation June 6, 2006

    Slide 1: Investor Presentation June 6, 2006

    Investor Presentation June 6, 2006 PHARMOS

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement The introductory remarks and the Company’s responses to questions will include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as “hope,” “may,” “believe,”

  3. Slide 3: Additional Information about the Merger and Where to Find It

    Slide 3: Additional Information about the Merger and Where to Find It

    Additional Information about the Merger and Where to Find It In connection with its merger with Vela Pharmaceuticals Inc., Pharmos has filed a preliminary proxy statement and other relevant materials with the Securities and Exchange Commission (SEC) relating to a meeting of shareholders. Investors a

  4. Slide 4: Pharmos Investment Highlights

    Slide 4: Pharmos Investment Highlights

    Pharmos Investment Highlights Focus on CNS (including brain-gut), pain, inflammation Significant market opportunity for leading IBS therapeutic Proprietary/novel cannabinoid library Strategic objective: Acquire later-stage assets Vela acquisition announced March 2006 Establishes leadership positions

  5. Slide 5: The Vela Acquisition Summary

    Slide 5: The Vela Acquisition Summary

    The Vela Acquisition Summary Fulfills strategic objective / excellent fit Expands pipeline – later stage clinical drugs Complements focus on CNS/inflammation Dextofisopam – successful Phase 2a in IBS Two additional later-stage assets Tianeptine – strong follow-on for IBS VPI-013 – Phase 2 asset for

  6. Slide 6: Deal Highlights

    Slide 6: Deal Highlights

    Deal Highlights Stock and cash transaction Initial payout: 11.5 million shares $5 million cash Performance milestones totaling 8 million shares 4 million on successful completion of Phase 2b 4 million on submission of NDA New board members Tony Evnin, Ph.D., of Venrock Associates Chuck Newhall III o

  7. Slide 7: The New Pharmos Pipeline

    Slide 7: The New Pharmos Pipeline

    The New Pharmos Pipeline Preclinical Phase 1 Phase 2 Phase 3 Dextofisopam IBS Tianeptine VPI-013 BF-036 Autoimmune Neuropathic Pain Topical NSAID’s * Nano Diclofenac for OA Nano Ketorolac for OA Cannabinor Nociceptive Pain Neuropathic Pain * Nano-Tech emulsion delivery IBS Female Sexual Dysfunction

  8. Slide 8: IBS Overview

    Slide 8: IBS Overview

    IBS Overview PHARMOS

  9. Slide 9: IBS: A Prevalent Disease

    Slide 9: IBS: A Prevalent Disease

    IBS: A Prevalent Disease 9.1 2.7 2.2 2.2 1.8 1.2 0.5 3.7 GERD IBS Peptic Ulcer Diverticular Disease Chronic Diarrhea Colorectal Cancer Crohn's Disease Ulcerative Colitis Source : Sandler et al. The burden of selected digestive diseases in the United States. Gastroenterology 122:1500-1511, 2002 (data

  10. Slide 10: IBS: A Significant Underserved Market

    Slide 10: IBS: A Significant Underserved Market

    IBS: A Significant Underserved Market Diarrhea- Predominant 36% Constipation- Predominant 31% Alternating Diarrhea and Constipation 33% 5-HT 3 Antagonist Lotronex ® (GSK) Indication: women / severe d-IBS Boxed warning: serious GI AEs (ischemic colitis) High constipation rate (29%) Registry 5-HT 4 Ag

  11. Slide 11: IBS: A Significant Underserved Market

    Slide 11: IBS: A Significant Underserved Market

    IBS: A Significant Underserved Market Diarrhea- Predominant 36% Constipation- Predominant 31% Alternating Diarrhea and Constipation 33% 5-HT 3 Antagonist Lotronex ® (GSK) • Sales: $10 - 12 million* 5-HT 4 Agonist Zelnorm ® (Novartis) • Sales: $370 - 380 million* * Projected 2006 Dextofisopam

  12. Slide 12: Dextofisopam

    Slide 12: Dextofisopam

    Dextofisopam PHARMOS

  13. Slide 13: Dextofisopam: Leading Asset in Development for IBS

    Slide 13: Dextofisopam: Leading Asset in Development for IBS

    Dextofisopam: Leading Asset in Development for IBS Novel mechanism – different from other IBS drugs Older drugs (antispasmodics, antidiarrheals) Peripherally-acting anticholinergics or opiates Questionable efficacy, side effect issues Newer drugs (Lotronex ® , Zelnorm ® ) Peripherally-acting seroton

  14. Slide 14: No Safe, Effective Drugs on Near Horizon: Other Later-stage Assets for IBS

    Slide 14: No Safe, Effective Drugs on Near Horizon: Other Later-stage Assets for IBS

    No Safe, Effective Drugs on Near Horizon Other Later-stage Assets in Development for IBS Phase 1 c-IBS completed (Oct 2005) Phase 2 Microbia MD-1100 Guanylate cyclase C agonist 5HT 3 partial agonist Phase 2 in c-IBS (Sep 2005) Phase 2 Dynogen DPP-773 Approved for travelers’ diarrhea Some efficacy in

  15. Slide 15: Dextofisopam: Proposed MOA Well Suited for IBS

    Slide 15: Dextofisopam: Proposed MOA Well Suited for IBS

    Dextofisopam: Proposed MOA Well Suited for IBS Regulates autonomic tone at the level of the hypothalamus via atypical 2,3-BZ receptors 2,3-BZ receptors Classical benzo X Anti-inflammatory

  16. Slide 16: Dextofisopam: Proposed MOA Well Suited for IBS

    Slide 16: Dextofisopam: Proposed MOA Well Suited for IBS

    Dextofisopam: Proposed MOA Well Suited for IBS Regulates autonomic tone at the level of the hypothalamus via atypical 2,3-BZ receptors 2,3-BZ receptors Classical benzo X Anti-inflammatory

  17. Slide 17: Dextofisopam: Phase 2a Study Design

    Slide 17: Dextofisopam: Phase 2a Study Design

    Dextofisopam: Phase 2a Study Design Double-blind, US study (33 sites) 141 men and women with diarrhea-predominant or alternating IBS 200 mg BID dextofisopam or placebo for 12 weeks Primary endpoint * : “adequate relief” Weekly… • Patient friendly, global measure • FDA accepted measure Secondary endp

  18. Slide 18: Dextofisopam: Phase 2a Study Results

    Slide 18: Dextofisopam: Phase 2a Study Results

    Dextofisopam: Phase 2a Study Design Positive effect on primary efficacy endpoint 32% advantage vs. placebo Statistically significant (p = 0.033) Positive effect on key secondary efficacy endpoints Dextofisopam decreased stool frequency and improved (hardened) stool consistency in patients with d-IBS

  19. Slide 19: Dextofisopam: A Potential First-line IBS Treatment

    Slide 19: Dextofisopam: A Potential First-line IBS Treatment

    Dextofisopam: A Potential First-line IBS Treatment Novel dual mechanism – not serotonergic Excellent patent position COM through 2019, many additional patents filed Strong Phase 2a data Successful End of Phase 2a FDA meeting Phase 2b dose-ranging trial planned

  20. Slide 20: Additional Assets

    Slide 20: Additional Assets

    Additional Assets PHARMOS

  21. Slide 21: Additional Vela Assets

    Slide 21: Additional Vela Assets

    Additional Vela Assets Tianeptine Follow-on to dextofisopam Preclinicals predict efficacy in IBS Potential to enter Phase 2 rapidly VPI-013 * Originally in development for depression Phase 2 trial missed depression endpoints Significantly improved sexual function Potential to develop for sexual dysf

  22. Slide 22: Cannabinor Overview

    Slide 22: Cannabinor Overview

    Cannabinor Overview Cannabinor: the first CB2 molecule to clinic Active - pain animal models Nociceptive, neuropathic & visceral Activity opioids & NSAIDs Active - autoimmune animal models RA, MS

  23. Slide 23: Cannabinor Clinical Trials

    Slide 23: Cannabinor Clinical Trials

    Cannabinor Clinical Trials Phase 1 trial completed (Dec 2005) IV formulation 48 healthy volunteers Linear pharmacokinetics Well tolerated Phase 2 pain trials in 2006 Nociceptive (Third molar extraction / 2Q2006) Neuropathic (4Q 2006) Optimizing oral formulation

  24. Slide 24: Potential CB2 Leadership

    Slide 24: Potential CB2 Leadership

    Potential CB2 Leadership NP, Cancer Inflammatory Visceral Pain < 50 Peripherally Restricted THC Asthma Allergy < 10 > 100 CB2 Antagonist Obesity < 10 > 0.002 CB1 Antagonist NP RA Spasticity Bowel/Bladder < 50 > 50 2 nd Generation (036) Post Op. Cancer Pain < 100 > 10 Cannabinor Potential Indication(

  25. Slide 25: Company Highlights

    Slide 25: Company Highlights

    Company Highlights PHARMOS

  26. Slide 26: Pharmos Trading/Financial Highlights

    Slide 26: Pharmos Trading/Financial Highlights

    Pharmos Trading/Financial Highlights NASDAQ: PARS 3 mo. avg. daily volume: 93,100 Market capitalization: $46.1 million Recent price: $2.42 (6/2/06) 52-week high/low: $1.94 - $2.93 Financial (Pre-acquisition): 19.1 million shares outstanding $41.6 million cash/short-term investments ($2.24 per share,

  27. Slide 27: Post-Vela Financial Highlights

    Slide 27: Post-Vela Financial Highlights

    Post-Vela Financial Highlights 30.5 million shares outstanding Performance milestone payments: 8 million shares 4 million shares: Successful completion Phase 2b 4 million shares: NDA submission < $40 million cash ($5 million to Vela shareholders) 2006 operational burn rate * = $19 - $20 million *Ass

  28. Slide 28: The Business Strategy

    Slide 28: The Business Strategy

    The Business Strategy Create progressive specialty pharma company Focus: selective CNS, pain,inflammation Implement actionable plan Aggressive business development initiatives Optimize pipeline Align resources Metrics and monitoring Expedite building upon new foundation Infuse talent Expand product

  29. Slide 29: Pharmos Investment Highlights

    Slide 29: Pharmos Investment Highlights

    Pharmos Investment Highlights Focus on CNS (including brain-gut), pain, inflammation Significant market opportunity for leading IBS therapeutic Proprietary/novel cannabinoid library Strategic objective: Acquire later-stage assets Vela acquisition announced March 2006 Establishes leadership positions

  30. Slide 30: Major Near-Term Milestones

    Slide 30: Major Near-Term Milestones

    Major Near-Term Milestones* 2006 Q2 Filed proxy for Vela acquisition Begin cannabinor Phase 2a nociceptive pain (third molar) trial Finalize dextofisopam Phase 2b IBS protocol Q3 Unblind data from cannabinor Phase 2a nociceptive pain trial Hold special shareholder meeting; close acquisition of Vela

  31. Slide 31: PHARMOS

    Slide 31: PHARMOS

    PHARMOS

Source: SEC EDGAR · 8-K filed Jun 6, 2006

More decks from Pharmos Corp